Radiopharm Theranostics and the University of Texas MD Anderson Cancer Center (MD Anderson) have launched a new company that will develop new therapeutic radiopharmaceuticals for cancer treatment.
Radiopharm Ventures will combine MD Anderson's proprietary technologies in antigen discovery and molecular imaging with Radiopharm's expertise in developing radiopharmaceuticals.
Initially, the venture will focus on developing at least four therapeutics based on MD Anderson intellectual property. The first potential candidate is a humanized immunoglobulin G antibody against the tumor-specific antigen B7-H3, also known as CD276, which is highly expressed in several common tumors but not in healthy cells. Preclinical studies suggest the candidate radiotherapeutic antibody is effective in eliminating resistant colorectal cancers in laboratory models.
Radiopharm Theranostics owns 51% of Radiopharm Ventures, and MD Anderson owns 49%. MD Anderson has granted a license to Radiopharm Ventures for patent and technology rights for development and commercialization, effective September 11, 2022.
The agreement between Radiopharm Ventures and MD Anderson includes royalty and milestone payment obligations that arise from the development and/or commercialization of licensed products. The costs will be shared by Radiopharm and MD Anderson, and both parties will share ownership of the resultant intellectual property.
